Skip to content

Market/Novel Tech

Aflibercept injection (8 mg, Eylea HD) for the treatment of macular oedema following retinal vein occlusion (RVO) meets primary endpoint. 

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have announced that aflibercept (injection 8 mg) met the primary endpoint for the treatment of patients with macular oedema following… Read More »Aflibercept injection (8 mg, Eylea HD) for the treatment of macular oedema following retinal vein occlusion (RVO) meets primary endpoint. 

EyePoint Pharmaceuticals announce interim results from a Phase 2 EYP-1901 treatment (a tyrosine kinase inhibitor with a sustained delivery insert) for DME patients.    

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), based in Watertown, Massachusetts, have announced positive interim 16-week data for an ongoing Phase 2 “VERONA” clinical trial, evaluating “DURAVYU”… Read More »EyePoint Pharmaceuticals announce interim results from a Phase 2 EYP-1901 treatment (a tyrosine kinase inhibitor with a sustained delivery insert) for DME patients.    

Ocuphire Pharma Inc., has acquired Opus Genetics, aimed to advance treatments quickly for several ophthalmic indications.    

Ocuphire Pharma, Inc. (Nasdaq: OCUP), based in Farmington Hills, Michigan, USA announced the all-stock acquisition of Opus Genetics, Inc., a private ocular gene therapy company… Read More »Ocuphire Pharma Inc., has acquired Opus Genetics, aimed to advance treatments quickly for several ophthalmic indications.    

HuidaGene Therapeutics presents a novel AAV9 RPE-65 treatment for Leber congenital amaurosis at EURETINA Congress in Barcelona.    

HuidaGene Therapeutics, based in Shanghai, China and Clinton, New Jersey, have  reported preliminary data on a novel gene therapy treatment for RPE-65 LCA (Leber congenital… Read More »HuidaGene Therapeutics presents a novel AAV9 RPE-65 treatment for Leber congenital amaurosis at EURETINA Congress in Barcelona.